First-line oral capecitabine therapy in metastatic colorectal cancer: A favorable safety profile compared with intravenous 5-fluorouracil/leucovorin

Annals of Oncology

Volumn 13, Issue 4, 2002, Pages 566-575

  Cassidy, J ^a   Twelves, C ^b   Van Cutsem, E ^c   Hoff, P ^d   Bajetta, E ^e   Boyer, M ^f   Rugat, R ^g   Burger, U ^h   Garin, A ⁱ   Graeven, U ^j   McKendrick, J ^k   Maroun, J ^l   Marshall, J ^m   Osterwalder, B ^h   Perez Manga G ⁿ   Rosso, R ^o   Rougier, P ^p   Schilsky, R L ^q  

^a UNIVERSITY OF ABERDEEN   (United Kingdom)

^b UNIVERSITY OF GLASGOW   (United Kingdom)

^c UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^d UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^e NATIONAL CANCER INSTITUTE   (Italy)

^f ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^g INSTITUT CLAUDIUS REGAUD   (France)

^h F HOFFMANN LA ROCHE LTD   (Switzerland)

ⁱ Russian Research Center   (Russian Federation)

^j RUHR UNIVERSITY BOCHUM   (Germany)

^k BOX HILL HOSPITAL   (Australia)

^l OTTAWA REGIONAL CANCER CENTRE   (Canada)

^m GEORGETOWN UNIVERSITY   (United States)

ⁿ HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^o UNIVERSITY OF GENOA   (Italy)

^p HÔPITAL AMBROISE PARÉ   (France)

^q UNIVERSITY OF CHICAGO   (United States)

more..

Author keywords

Capecitabine; Colorectal cancer; Fluoropyrimidine; Tolerability

Indexed keywords

CAPECITABINE; CREATININE; FLUOROURACIL; FOLINIC ACID; TEGAFUR; URACIL;

ADULT; AGE; AGED; ALOPECIA; ARTICLE; CANCER GROWTH; CANCER SURVIVAL; CLINICAL TRIAL; COLORECTAL CANCER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE CLEARANCE; DATA ANALYSIS; DISEASE SEVERITY; DOSE KIDNEY FUNCTION RELATION; DOSE RESPONSE; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG POTENCY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; GASTROINTESTINAL SYMPTOM; HAND FOOT SYNDROME; HUMAN; INCIDENCE; MALE; METASTASIS; NEUTROPENIA; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL;

ADMINISTRATION, ORAL; ADULT; AGED; AGED, 80 AND OVER; ANTIMETABOLITES, ANTINEOPLASTIC; COLORECTAL NEOPLASMS; DEOXYCYTIDINE; DISEASE PROGRESSION; FEMALE; FLUOROURACIL; HUMANS; INJECTIONS, INTRAVENOUS; LEUCOVORIN; MALE; MIDDLE AGED; SURVIVAL ANALYSIS;

EID: 0036235128     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/annonc/mdf089     Document Type: Article

References (13)

1. Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue
2. Multicenter phase III study of 5-fluorouracil (5-FU) or UFT™ in combination with leucovorin (LV) in patients with metastatic colorectal cancer
3. Preferential activation of capecitabine in tumor following oral administration in colorectal cancer patients
4. Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer
5. Multicenter, phase II study of capecitabine in taxane-pretreated metastatic breast cancer
6. Capecitabine, an oral fluoropyrimidine carbamate with substantial activity in advanced colorectal cancer: Results of a randomized phase II study
7. Oral capecitabine compared with intravenous 5-fluorouracil plus leucovorin (Mayo Clinic regimen) in patients with metastatic colorectal cancer: Results of a large phase III study
8. Comparison of oral capecitabine (Xeloda®) v intravenous 5-fluorouracil plus leucovorin (Mayo Clinic regimen) as first-line treatment in 605 patients with metastatic colorectal cancer: Results of a randomized phase III study
9. Capecitabine as first-line treatment for colorectal cancer (CRC): Integrated results of 1207 patients (pts) from 2 randomized, phase III studies
10. Prediction of creatinine clearance from serum creatinine
11. Pharmacology of fluorinated pyrimidines: Eniluracil
12. Effect of hepatic dysfunction due to liver metastases on the pharmacokinetics of capecitabine and its metabolites